Karyopharm announce Xpovio meets endpoints in Phase III trial

The pharmaceutical company announced positive top-line results from the randomised Phase III BOSTON study of Xpovio (selinexor). The drug in combination with once-weekly Velcade (bortezomib) and low-dose dexamethasone (SVd) met its primary endpoint of a statistically significant increase in progression-free survival (PFS) compared to standard twice-weekly Velcade plus low-dose dexamethasone (Vd). The trial saw the

Continue Reading